In Western countries about one of 11 women will develop a breast carcinoma in their lifetime. Despite considerable progress in tumor detection as well as in radio-, chemo-, and hormone therapy, more than one third of patients still succumb to the disease. In most cases death results from the dissemination of cancer cells and their proliferation at secondary sites.
INTRODUCTION
In Western countries about one of 11 women will develop a breast carcinoma in their lifetime. Despite considerable progress in tumor detection as well as in radio-, chemo-, and hormone therapy, more than one third of patients still succumb to the disease. In most cases death results from the dissemination of cancer cells and their proliferation at secondary sites.
To ensure a better characterization and treatment of the extensively heterogeneous breast tumors, new approaches are needed to complement the classical clinicopathological analysis. In particular, tools that exploit the most recent molecular biology knowledge and technological advances would be required. They should mainly help the clinician to predict, at the highest level of precision, the evolution of tumors, including their sites of metastasis, as well as the response of these tumors to different therapies. Moreover, they could accelerate the development of novel therapeutic agents, since this process increasingly requires the understanding of the molecular bases of breast cell transformation and tumor development.
One major objection raised against the generalized use of new technologies in the oncological routine is their cost. In this paper we examine how this problem might be solved in the peculiar case of the DNA microarray. We suggest the design of a breast cancer-oriented microarray carrying a limited number of oligonucleotide sequences specific to recognized or potential markers in breast oncology. By screening the medical literature, we have identified and listed about 250 of these markers.
MOLECULAR MARKERS
Current tumor characterization procedures include clinical examination, imaging, microscopic analysis (cytology, study of tumor margins) -all providing mainly qualitative data -and the measurement of a few specific molecules (molecular markers) by immunohistochemical, biochemical, and molecular biology techniques, the latter providing quantitative or semiquantitative data.
There is a growing need for additional reliable molecular markers, since the perfect marker for breast cancer may not even exist. As a matter of fact, the ideal marker should be produced solely by cancer cells or in their immediate vicinity; it should be specific and sensitive, and easily measurable in a reproducible way through simple, fast, and inexpensive techniques; it should allow estimation of the tumor volume and assessment of the efficacy of therapy and might itself constitute a highly tumor-specific therapeutic target. In reality, the highly heterogeneous nature of breast tumors makes their exhaustive description based on the expression levels of only a few genes impossible. This is further hampered by the diversity of processes (proliferation, adhesion, proteolysis, chemoresistance, hormone sensitivity) that characterize tumor behavior. Accounting for the complexity of tumors undoubtedly requires recourse to a panel of selected indicators.
Studies in the last 10 years have unveiled the great molecular complexity of breast carcinomas. Thousands of human genes have been cloned and characterized from various sources. For more than 250 of them, listed in Table I , it has been shown that their corresponding mRNA and/or protein level may vary in breast tumors or cell lines. These variations can, or potentially could -help to identify and characterize tumors (diagnostic markers, or indicators); -allow to foresee the evolution and the complicationsnotably metastasis -of tumors (prognostic markers); -provide an estimation of the patient's responsiveness to specific therapy (predictive markers).
Besides their possible value as clinical indicators, some of these markers could also be used as therapeutic targets.
For a given molecular marker to earn the label of "reliable clinical marker" it must undergo extensive, strictly controlled and reproducible expression studies, often covering years. To date this process has been completed for a few candidates only. For instance, the longest established breast cancer molecular indicator, the estrogen receptor-alpha (ER-alpha, gene ESR1), has been quantified for more than 30 years in tumor samples. This has led to its definitive acceptance both as a prognostic indicator (its expression is associated with longer survival) and a predictor of patient responsiveness to antiestrogens, particularly in node-negative patients (reviewed in (1)). cerbB-2 (ERBB2) is another marker whose prognostic relevance has been demonstrated by numerous studies. More recently, it has been suggested that its overexpression, observed in 10% to 40% of breast tumors, might predict patient responsiveness to chemotherapeutic agents such as doxorubicin and paclitaxel (reviewed in (2)). However, confirmation of the latter property requires further investigation. Thus, the c-erbB-2 expression level may at present be considered both a recognized (for prognosis) and a potential (for prediction) reliable indicator. Moreover, c-erbB-2 could also serve as a target for antibody-based therapeutic strategies, which emphasizes the need to evaluate its expression level in all tumor samples. Urokinase-type plasminogen activator (uPA, gene PLAU) and plasminogen activator inhibitors-1 and 2 (SERPINE1 and SERPINB2) are three additional markers that have recently been introduced into the clinical routine after extensive investigation of their expression levels in breast tumors. They all possess prognostic and predictive properties. Moreover, uPA might be the target of therapeutic strategies based on the use of antiproteases (reviewed in (3)).
The clinical importance of several other markers has also been repeatedly suggested by studies examining variations in their mRNA and/or protein amounts in tumors. Among these are bcl-2 (gene BCL2), cathepsin D (CTSD), cyclin D1 (CCND1), epidermal growth factor receptor (EGFR), p53 (TP53), progesterone receptor (PgR), pS2 (TFF1), and urokinase receptor (PLAUR) (3) (4) (5) .
Apart from the few markers that are generally recognized as reliable clinical indicators, a vast majority still require extensive investigation before acquiring (or not) this status. In view of the great amount of work involved in such studies, we clearly have to consider the opportunity of using recently developed techniques for massive, parallel, rapid, and standardized determination of gene expression in biological samples. These techniques might be helpful not only to clinicians but also to basic researchers wishing to gain access to the expression of a large number of tumor molecules in order to improve their knowledge of pathways underlying the occurrence and evolution of breast carcinomas.
MARKER ANALYSIS -DNA MICROARRAY
Gene expression may be measured at both transcriptional (mRNA) and translational (protein) levels. Because they ultimately support cell functions and tumor properties such as growth, angiogenesis, and dissemination, proteins and enzyme activities are the target of choice for investigations in tumor samples. Indeed, their systematic and large-scale measurement should be performed in the future by techniques including antibody-based arrays, allowing the simultaneous measurement of multiple proteins in a sample (6) ; tissue arrays, to measure one protein in multiple tumor samples (7, 8) ; and, more generally, proteomics. The latter term refers to the description of proteome (protein expression level and post-translational modifications) by the association of 2D electrophoresis, laser, mass spectrometry, and computerized image and data analysis (9, 10) . Although promising, such methods are cumbersome and time-consuming and require further technical development before being applicable on a large scale and at a reasonable cost. At present it is easier to assay for gene expression in a biological sample by qualitative and quantitative analysis of its mRNA population (transcriptome). This may be performed through the use of the so-called DNA microarrays or DNA biochips 
CSE1L
Chromosome segregation 1-like; Cell cycle regulation 20q13 10969801 Cellular apoptosis susceptibility protein (Cas)
CSF1
Colony stimulating factor 1; 1p21-1p13 1334964 Macrophage-colony stimulating factor (M-CSF, M-CSF1)
CSF1R
Colony stimulating factor 1 receptor; 5q33-5q35 1334964 c-fms-encoded protein
CSPG2
Chondroitin sulfate proteoglycan 2; 5q12-q14 10353737 Versican
CST6
Cystatin E/M Proteolysis 11q13 8995380 
CSTA
NCOA1 Nuclear receptor coactivator 1; Hormone sensitivity 2p23 9541193 Steroid receptor coactivator 1 (SRC-1) NCOA2 Nuclear receptor coactivator 2; Hormone sensitivity 8 10612426 Steroid receptor coactivator 2 (SRC-2); Transcriptional intermediary factor 2 (TIF2); Glucocorticoid receptor interacting protein 1 (GRIP1) NCOA3 Nuclear receptor coactivator 3; Hormone sensitivity 20q12 9252329 Steroid receptor coactivator 3; Amplified in breast cancer (AIB1); Thyroid hormone receptor activator molecule (TRAM-1); Receptor-associated coactivator 3 (RAC3)
NCOR1
Nuclear The list has been composed by extensive screening of the medical literature covering the last 15 years. For each marker the following items are mentioned: the main gene name as recommended by the Human Genome Organisation (HUGO, http://www.gene.ucl.ac.uk/hugo/); one or more denomination(s) of the gene product, as found in the breast cancer literature; one tumor property or cell function in which the marker is involved, if this is known; the gene locus; the PubMed identificator (PMID) of one of the most recent references reporting a variation of the marker mRNA in breast tumors or breast cancer cell lines. PubMed URL: http://www.ncbi.nlm.nih.gov/PubMed/ (reviewed in (11)).
DNA microarrays are solid surfaces bearing multiple cDNA or oligonucleotide spots, which play the role of capture probes. These capture probes, which represent genes or parts of genes, are either chemically synthesized in situ on the surface (oligonucleotide-based arrays) or laid down through the use of a special device, the "arrayer" (cDNA-based arrays). Glass and plastic slides are progressively replacing nylon membranes as supports.
cDNA-based microarrays are ideal for extensive screening of gene expression and expression profiling of unknown or poorly characterized genes. They may be very useful to examine cell or tissue response to various agents, to identify new therapeutic targets, or to classify biological materials (such as tumors). In these arrays the capture sequences are obtained from cDNA libraries or PCR products, and are thus generally heterogeneous in size. This may make any direct quantitative comparison between two different genes represented on the array impossible. Moreover, in some cases the capture sequences may be unable to discriminate between different genes exhibiting common or closely related regions, or between variants of the same gene. This would require the design and use of gene-specific hybridization probes. Oligonucleotide-based microarrays are best suitable for expression studies of one or a few well characterized genes. Usually the capture sequences supported by such arrays have the same size. This allows quantitative comparisons between two genes or two variants of the same gene represented on the array. Capture sequences may be chosen to fit to highly specific gene regions and multiple sequences corresponding to different regions may be used for each gene. However, this operation may be tedious and time-consuming.
In most studies involving microarrays, labeled target cDNAs obtained by reverse transcription from the population of tumoral mRNAs are incubated with the array, and the amount of material hybridized to the specific capture probes is determined by various techniques (radioactivity, colorimetry, fluorescence and others). Microarrays have the inherent advantage of detecting the expression of genes in parallel, with a direct readout of the hybridization results. Most of the commercially available DNA microarrays carry several thousands of capture probes; due to this vast amount of sequences to be synthesized, purified, quantified, and fixed on the solid support, they are expensive. They also entail rather complicated data analysis. Moreover, they may carry many capture probes devoid of real interest from a perspective of routine breast cancer evaluation, because these are specific to genes that are unexpressed or invariable, or whose expression level has never been explored in this kind of cancer. Thus, although these "high-density" DNA microarrays may provide the basic researcher with a means to identify possible novel mRNAs transcripted in tumors, they do not provide a data/price ratio high enough to satisfy clinicians requiring a tool applicable to routine analysis in their everyday clinical activities.
A LOW-DENSITY BREAST CANCER-RELATED MICROARRAY
The concept of the low-density microarray is an attempt to reconcile the need for large amounts of breast cancer-relevant data with the need for low cost. A lowdensity microarray should support no more than a few hundreds of oligonucleotide capture sequences. However, these should be specific to markers that are recognized as reliable clinical indicators or serious candidates for this status on the basis of previous work. Since potential or established clinical markers continue to be the subject of fundamental studies, the low-density microarray could also be useful for basic researchers.
Due to their reduced number of capture sequences, low-density microarrays appear to be more suited for "customization" than high-density ones. For instance, it is conceivable to replace one capture probe by another on such arrays if, in the course of studies, the original sequence turns out to be not as interesting as initially suggested. Moreover, the possibility to select the probes one by one should allow the design of arrays specially dedicated to the study of one specific tumor characteristic such as angiogenesis, proliferation, or proteolysis.
The estrogen receptors (ER) alpha and beta and their functionally related molecules provide a good example of how a low-density DNA chip could be exploited by both clinicians and basic researchers working on breast cancer. In addition to the reliable clinical indicator ER-alpha and the more recently identified ER-beta (gene ESR2), it is recommended to analyze tumors for the expression of several genes whose transcription is known to be induced by ER. For instance, levels of mRNA encoded by TFF1, CTSD, CCND1, PGR, and MYC are relevant to the transcriptional functionality of the ER. The possibility of using the expression of these genes as predictors of patient response to endocrine therapy is thus open and has to be validated.
Other mRNAs have been suggested to be under estrogenic regulation in breast cancer cells. Among them are keratin 19 (gene KRT19), parathyroid hormone-related peptide (PTHLH), interleukin-6 (IL6), vascular endothelial growth factor (VEGF) and bcl-2 (BCL2) (12) (13) (14) (15) (16) . Before they can be confirmed as reliable clinical indicators, their expression in tumors should be thoroughly examined.
Recent findings indicate that the activity of ER in response to estrogens/antiestrogens depends on the expression of several coactivator and corepressor molecules (17, 18) . These molecules are currently under extensive investigation. The understanding of their mechanisms of action may benefit from systematic studies of their expression in tumors and the resulting data could probably modulate the endocrine therapy given to patients.
The number of genes whose expression is more or less related to the presence and function of ER in tumors is indeed so high that it could almost justify the production of an ER chip, which would constitute a specialized form of a breast cancer-specific chip.
CHOICE OF MARKERS
mRNAs that could be candidates (see Table I ) for quantification by the low-density microarray are expected to fulfill four criteria: -Their levels should vary in breast cancer tissues or cells compared to their normal counterparts, or from one tumor to another, or at least from one cell line to another (e.g. MCF-7 versus MDA-MB-231); -These variations should be recognized as being, or at least suspected to be, of diagnostic, prognostic, or predictive significance; -They should be expressed in tumors at levels detectable by the DNA chip. This requirement might become a limiting factor due to the decreasing size of samples obtained at surgery. The total RNA amount routinely used to label radioactive or fluorescent target cDNA for microarray hybridization may be as low as 1 or 50, respectively. With such amounts, however, some specific mRNAs whose basal level is low (as is notably the case for cytokines) could be undetectable. Amplification of the mRNA sequences could solve this problem but introduces an additional level of manipulation and very often negatively affects the quantification since not all mRNA sequences are amplified with the same efficiency. -The variations in their levels should parallel the variations in the corresponding protein and gene levels. Basically, the amount of mRNA reflects an equilibrium between transcription and degradation, which is influenced by many factors. This amount may also be determined by gene deletions and amplifications (frequently observed for genes like ERBB2, MYC, CCND1, EMS1, FGFR1, and MDM2 (19)). Proteic structures and activities are the ultimate support of cell functions and tumor properties. A good correlation between mRNA and protein levels may be crucial when it concerns therapeutic target proteins, such as proteinases, vascular endothelial growth factor (VEGF), c-erbB-2 (ERBB2), or resistance markers such as breast cancer resistance protein (ABCG2), multidrug resistance protein-1 (ABCB1) or the lung resistance protein (MVP). Regarding ER-alpha (ESR1) we have recently shown that a simple linear relationship exists between its 6.7-kb mRNA measured by Northern blot and the receptor level evaluated by ligand-binding assay (LBA) (20) . However, similar studies remain to be done for a number of candidate markers. This means that, besides results obtained at the mRNA level, it will be mandatory to measure the corresponding protein in tumor samples. The use of DNA chips should lead to a first selection of markers and to the elimination of candidates for which a protein study will not be necessary.
CHOICE OF CAPTURE PROBES
Size, cost of production, time needed for efficient hybridization with the target cDNA, and specificity are determinant factors in the choice of a capture probe. In some cases the constraints defined by these factors may be difficult to be reconciled.
In theory, longer probes lead to more efficient hybridization but they also require longer hybridization times and are more expensive. Furthermore, it may happen that a capture probe must absolutely be short because its target cDNA itself is short. For instance, FGF2, PIP (encoding prolactin-induced protein), MGB1 (mammaglobin 1), TFF1 (pS2), and SPRR1A (small proline-rich protein 1A) are transcribed into mRNAs that do not exceed 500 bases.
Retrotranscription of mRNAs begins at their 3'-poly(A+) region and is not always complete, which gives rise to a population of more or less complete cDNAs. To improve the efficiency of hybridization it may thus be preferable to design capture sequences specific to mRNA regions close to their 3' end. On the other hand, care must be taken to avoid regions of high (>50%) homology between genes, able to lead to cross-hybridization between capture probes and target cDNAs. Homologies between mRNA species are often found in regions encoding highly conserved protein domains, such as transmembrane or catalytic portions. This is exemplified by the estrogen receptors alpha and beta, whose DNA-binding domains show up to 84% homology at the nucleotide level, while these receptors are largely unrelated by their N-terminus (21) .
VARIANTS
It may happen that multiple mRNAs are transcribed from the same gene. These variants often exhibit more or less overlapping sequences. When selecting one or more capture probes specific to such a marker, one should wonder whether all variants have the same potential importance as diagnostic, prognostic, or predictive indicators, or whether it is recommended to detect only some specific ones.
For instance, two integrin alpha 6 (ITGA6) mRNA variants have been identified in breast tumors. They encode proteins differing by their C-terminal cytoplasmic domain (22) . Increased integrin alpha 6 expression could be associated with the metastatic phenotype of breast cancer cells (23) , but this has not been specifically ascribed to any of the variants. Similarly, the potential prognostic value of bcl-2 (BCL2) in breast cancer (5) has not been clearly associated with either of its two transcripts, which differ by their C-terminus. For ITGA6 as well as BCL2 it thus appears appropriate to design a capture probe recognizing both variant mRNAs.
At least four variants (A to D) have been found for the integrin beta 1 (ITGB1), which mediates interactions between cells and the extracellular matrix. The relative amount of these forms is likely to vary in breast tumors. However, it is clearly recommendable to detect the C variant, which has been shown to inhibit cell proliferation in vitro and is downregulated in carcinomas (24) . Two capture probes should therefore be designed, one specific to the C form, the other detecting all ITGB1 variants.
A number of more or less truncated ER-alpha mR-NA variants have been described in breast tumors, mainly on the basis of RT-PCR studies. There is no evidence that these rare (25) small-sized forms specify any functional protein. On the other hand, very little is known about their potential as diagnostic, prognostic or predictive factors (26) . While the design of a capture probe recognizing the major full-size ER-alpha is an absolute requirement for a breast cancer-specific chip, it might thus be of interest to define additional probes specific to the different variants. Such probes could ideally be incorporated into an even more specialized estrogen receptor-related array.
CD44 glycoproteins are involved in cell-cell and cell-matrix interactions. The CD44 gene contains 20 exons. Exons 1-5 and 16-20 are spliced together to form a transcript that encodes the ubiquitously expressed standard isoform (known as CD44s). The ten variable exons 6-15 (also named v1-v10) can be alternatively spliced and included within the standard exons at an insertion site between exons 5 and 16, giving rise to a large number of so-called CD44v variants (27) . Preliminary studies suggest that not all variants have the same interest as indicators in breast cancer. According to these studies it is recommended to at least define a capture probe recognizing the CD44v6 variant, which might be a marker to identify node-negative patients with a relatively favorable prognosis (28) . It has also been suggested that the CD44v7-v8 variant could direct breast tumor cells to lymph nodes and lymphatic vessels (29) and it should be measured by a specific probe.
The case of MUC1 is one of the most complicated ones. This gene encodes at least three proteins, Muc1/y, Muc1/sec, and Muc1/rep. The latter two contain a large, highly glycosylated core region made up of 30-100 tandem repeats of a 20-amino-acid sequence (30) . All Muc1 proteins appear to play a role in reducing cell-cell and integrin-mediated cell-matrix interactions, and probably in the metastatic spread of cancer cells from the primary tumor site. More generally, MUC1 expression might enhance tumor initiation and progression. Muc1 proteins could also serve as targets for immunotherapy using antibodies directed against the glycosylated variable core region. Molecular studies have shown that the non-secreted Muc1/rep and the secreted Muc1/sec are able to bind to Muc1/y serving as a signaling receptor. This suggests that the impact of MUC1 on tumor properties could depend on the relative levels of its three protein products. While the design of a unique capture probe recognizing all MUC1 mRNAs is practically possible, it would be of considerable interest to specifically detect the messengers encoding the three proteins Muc1/y, Muc1/sec and Muc1/rep.
CONCLUSION
Besides the traditional clinicopathological analysis, reliable molecular markers will be increasingly used, alone or in combination (index), for diagnosis, prognosis, and response prediction in breast oncology. We need to increase the number of available markers and thus to validate new, potentially interesting ones. To achieve this aim the availability of simultaneous, fast, and standardized tumor sample analysis techniques that are routinely applicable appears greatly helpful. While proteome analysis ("proteomics") is a major challenge for the future, a low-density breast cancer-specific DNA microarray appears currently to best combine the above-mentioned imperatives with the necessity of an inexpensive and easy-to-use tool. On the other hand, the design of pertinent capture probes, discriminating between closely related markers and/or variant forms, may be a fastidious step in the development of such a tool. Nevertheless, specialized low-density microarrays are now under development and are expected to become, with the aid of computer-based data interpretation, a mandatory complement to future proteomics. 
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